A surgical training device (100), in particular for simulating a pyeloplasty operation, more in particular for simulating a pyeloplasty operation in paediatric age, comprising a first structure (10) adapted to simulate at least one renal parenchyma (11), a main renal artery (12) and an inferior polar artery (13), and a second structure (20) adapted to simulate a renal pelvis (21), a pyelo-ureteral junction (22) and at least partially a ureter (23), wherein the second structure (20) comprises a ureteral defect adapted to undergo a surgical training procedure. The first structure (10) and the second structure (20) are mechanically coupled to each other in a reversible manner so that, after undergoing a surgical training procedure, the second structure (20) can be replaced, in particular independently of the first structure (10).
The present invention relates to a process for the preparation of a biopolymer obtained from the cutin contained in tomato skin and the applications thereof for the production of biomedical devices and products for personal hygiene.
3.
NEW BORON-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
The present invention relates to new boron-based compounds for the treatment of Alzheimer's disease by irradiation with neutrons amplified by neutron capture reactions (Capture-Enhanced Neutron Irradiation, CENI), and the relative preparation methods.
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
4.
METHOD FOR THE PRODUCTION OF A SHAPE-MEMORY TISSUE AND RELATIVE USES
The present invention consists of a method for the production of a shape-memory tissue through the use of polymeric matrices capable of temporarily modifying their shape, following the application of an external stimulus, and at the same time capable of supporting the vehiculation of cells and/or drugs.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
D01D 5/00 - Formation des filaments, fils ou similaires
D01F 6/62 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiques; Leur fabrication à partir de produits d'homopolycondensation à partir de polyesters
D01F 6/84 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiques; Leur fabrication à partir de produits de copolycondensation à partir de copolyesters
D01F 6/92 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiques; Leur fabrication à partir de mélanges de produits de polycondensation comme constituant majeur avec d'autres polymères ou des composés de bas poids moléculaire de polyesters
5.
NOVEL FORMULATIONS FOR BIOBASED NANOSTRUCTURED FILMS AND COATINGS
The present invention refers to novel compositions based on deacetylated chitin nanowhiskers (CsNWs) as well as to processes for their preparation. Furthermore, the invention relates to a process for preparing films or coatings starting from said compositions as well as to biomedical, cosmetic articles based upon said compositions and uses thereof.
The present invention relates to silk fibroin bioinks specifically formulated for use in 3D bioprinting and the production of ex-vivo models capable of supporting hematopoiesis and the production of platelets and blood cells.
Vascular simulation device (100) for medical training of ultrasound-guided procedures, in particular for realistically simulating ultrasound-guided medical manoeuvres of puncturing blood vessels in an inguinal-femoral region and/or a subclavian/axillary region. The device (100) comprises at least a first vascular structure (40) adapted to let a fluid flow and to simulate an artery, in particular a femoral artery or a subclavian-axillary artery, a second vascular structure (20) adapted to let a fluid flow and to simulate a vein, in particular a femoral vein or a subclavian-axillary vein, and a structure (10), made with a mixture of ballistic gel and graphite or agarose and graphite or silicone and graphite and having echogenic properties, adapted to house at least partially the first vascular structure (40) and the second vascular structure (20). Advantageously, the first vascular structure (40) and/or the second vascular structure (20) are adapted to be fluidically connected to an extracorporeal circulation circuit with circulating liquid (typically a heart-lung machine).
The process for the preparation of low- dimensional perovskite with preferential orientation comprises the phases of: supply of at least a first precursor (A) comprising inorganic iodide; supply of at least a second precursor (B) comprising organic iodide; supply of at least a third precursor (C) selected from at least one of methylammonium iodide and methylammonium chloride; mixing the first precursor (A), the second precursor (B) and the third precursor (C) with at least one solvent selected from the list comprising: N- dimethylformamide (DMF), dimethyl sulfoxide (DMSO), gamma- butyrolactone (GBL) and ethanol (Et-OH) to obtain a precursor mixture; heating of the precursor mixture to a temperature below 100°C; cooling of the precursor mixture; deposition and accretion of the precursor mixture to obtain low-dimensional perovskite with preferential orientation.
H10K 30/40 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire comprenant une structure p-i-n, ayant p. ex. un absorbeur pérovskite entre des couches de transport de charge de type p et de type n
9.
PYRIDINE-2-THIOL 1-OXIDE DERIVATIVES AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS CAUSED BY MYCOBACTERIUM OR FUNGI
The present invention relates to silk fibroin-based scaffolds suitable for supporting the 3D culture of human hematopoietic stem and progenitor cells and/or the production of blood cells ex-vivo, and methods for producing the same.
The present invention relates to covalently cross-linked glycosylated mucin nanoparticles and the use thereof for the delivery and release of active ingredients, markers and/or biomolecules. The subject matter of the invention also relates to covalently cross-linked glycosylated mucin nanoparticles comprising at least one compound selected from an active ingredient, a marker and a biomolecule. The invention further relates to a method for preparing covalently cross-linked glycosylated mucin nanoparticles, optionally comprising at least one compound selected from an active ingredient, a marker and a biomolecule.
The device (100) serves for removing virus particles in an air flow and comprises a tubular member (10) and an envelope (20). The tubular member (10) has an inlet (11) at an end portion and a plurality of outlets (12) at an outer lateral surface and the envelope (20) surrounds totally or partially the tubular member (10). The envelope (20) comprises a gas- permeable and liquid-impermeable membrane and contains virucidal liquid, in particular benzalkonium chloride, more in particular a 5% by weight aqueous solution of benzalkonium chloride. The device is configured so that air enters through the inlet (11), flows in the tubular member (10), escapes through the outlets (12), diffuses in the virucidal liquid, and exits through the gas-permeable and liquid-impermeable membrane of the envelope (20).
A61L 9/14 - Désinfection, stérilisation ou désodorisation de l'air utilisant des substances vaporisées ou pulvérisées
B01D 47/00 - Séparation de particules dispersées dans l'air, des gaz ou des vapeurs en utilisant un liquide comme agent de séparation
F24F 8/133 - Traitement, p.ex. purification, de l'air fourni aux locaux de résidence ou de travail des êtres humains autrement que par chauffage, refroidissement, humidification ou séchage par séparation, p.ex. par filtrage utilisant un filtrage humide par contact direct avec un liquide, p.ex. avec un liquide pulvérisé
The invention relates to a polymer film obtainable from the crosslinking reaction between pectin and carboxymethylcellulose in the presence of an organic calcium salt and a plasticiser. The film can comprise zeolite, loaded or not loaded with silver ions. The organic calcium salt is selected from: calcium propionate, calcium acetate, calcium lactate, calcium sorbate, calcium glutamate, calcium oleate, calcium palmitate, calcium laurate, calcium stearate and calcium myristate. The plasticising agent is a saturated or unsaturated fatty acid selected from: oleic acid and palmitic, stearic, lauric, myristic, myristoleic, palmitoleic and linoleic acid; polyethylene glycol; glycerol; glycerol derivatives; and citric acid salts, preferably sodium citrate. The polymer film can be laminated to at least one film/layer of plastic material, possibly biodegradable, or to a layer of paper and used for packaging foods, in particular baked products, with the aim of preserving them and extending their shelf life.
B32B 27/28 - Produits stratifiés composés essentiellement de résine synthétique comprenant des copolymères de résines synthétiques non complètement couverts par les sous-groupes suivants
14.
COMPOSITE COATING MATERIAL, PARTICULARLY FOR SOLAR CELLS
The composite coating material, particularly for solar cells, comprises at least one polymeric matrix and at least one metal-organic framework embedded in the polymeric matrix itself.
UNIVERSITA DEGLI STUDI DI MILANO - BICOCCA (Italie)
Inventeur(s)
Collina, Simona
Rossi, Daniela
Linciano, Pasquale
Rossino, Giacomo
Listro, Roberta
Peviani, Marco
Rossi, Silvia Stefania
Vigani, Barbara
Cavaletti, Guido Angelo
Miloso, Mariarosaria
Malacrida, Alessio
Abrégé
The present invention is comprised in the field of medicinal chemistry, and it is related to substituted vinyl piperazine-piperidine urea compound which are well effective as antitumoral agents. In particular, they are suitable in methods of treatment of glioblastoma (GB), multiple myeloma (MM) or pancreatic cancer (PC).
The present invention is comprised in the field of medicinal chemistry, and it is related to substituted vinyl piperazine-piperidine urea compound which are well effective as antitumoral agents. In particular, they are suitable in methods of treatment of glioblastoma (GB), multiple myeloma (MM) or pancreatic cancer (PC).
C07D 295/215 - Radicaux dérivés d'analogues azotés de l'acide carbonique
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
The present invention consists of a method for the production of a shape-memory tissue through the use of polymeric matrices capable of temporarily modifying their shape, following the application of an external stimulus, and at the same time capable of supporting the vehiculation of cells and/or drugs.
D01D 5/00 - Formation des filaments, fils ou similaires
A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
D01F 6/84 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiques; Leur fabrication à partir de produits de copolycondensation à partir de copolyesters
D01F 6/92 - Filaments, ou similaires, faits par l’homme, à un seul composant, formés de polymères synthétiques; Leur fabrication à partir de mélanges de produits de polycondensation comme constituant majeur avec d'autres polymères ou des composés de bas poids moléculaire de polyesters
19.
METHOD FOR THE IDENTIFICATION OF THE WHOLE SEQUENCE OF THE VARIABLE REGION OF THE HEAVY AND LIGHT CHAINS OF IMMUNOGLOBULINS
The present invention relates to a method for the identification of the whole nucleotide sequence of the variable region of the heavy and or light chains of immunoglobulins in a biological sample and the quantification of their relative frequency. The invention is particularly used for the identification of monoclonal heavy and light chains, i.e. tumours, in biological samples from patients suffering from a monoclonal gammapathy.
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p.ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
20.
3D-PATTERNED FIBER MATERIAL FOR THE TOPICAL DELIVERY OF NUCLEIC ACID AND THE PROCESS FOR ITS PREPARATION
A61L 15/26 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone; Leurs dérivés
A61L 31/06 - Matériaux macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 31/12 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
C09B 23/08 - Colorants méthiniques ou polyméthiniques, p.ex. du type cyanine caractérisés par la chaîne méthinique contenant un nombre impair de groupes CH plus de trois groupes CH, p.ex. polycarbocyanines
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures is provided. The three-dimensional substrate includes a diffusion system having a first apical compartment placed above a second basolateral compartment, the first and second compartments being separated by a semipermeable membrane, a base solution comprising polysaccharides, proteins and salts or a preformed hydrogel comprising polysaccharides, proteins and salts, and a cross-linking medium comprising salts, culture media and distilled water. A method for preparing a three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures is also provided.
A process for producing a photosensitive resin for 3D printing includes: (i) treating a vegetable oil with a polyol to form a monoglyceride, (ii) reacting the monoglyceride of step (i) with an unsaturated reagent to form a liquid resin with viscosity lower than 20 Pa·s at the temperature of 20° C., and (iii) mixing the liquid resin with a comonomer and a photoinitiator, as well as the photosensitive resin for 3D printing obtainable from such process and the 3D object obtainable from such photosensitive resin.
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
C07C 67/08 - Préparation d'esters d'acides carboxyliques par réaction d'acides carboxyliques ou d'anhydrides symétriques avec le groupe hydroxyle ou O-métal de composés organiques
The present invention relates to covalently cross-linked glycosylated mucin nanoparticles and the use thereof for the delivery and release of active ingredients, markers and/or biomolecules. The subject matter of the invention also relates to covalently cross-linked glycosylated mucin nanoparticles comprising at least one compound selected from an active ingredient, a marker and a biomolecule. The invention further relates to a method for preparing covalently cross-linked glycosylated mucin nanoparticles, optionally comprising at least one compound selected from an active ingredient, a marker and a biomolecule.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament
A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
The present invention relates to a method for simulating coronary changes and/or for assessing the risk of myocardial ischemia, preferably dynamic stress-induced ischemia.
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
A61L 15/26 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone; Leurs dérivés
A61L 15/46 - Désodorisants ou produits pour neutraliser les mauvaises odeurs, p.ex. pour inhiber la formation d'ammoniac ou la multiplication de bactéries
A61K 8/02 - Cosmétiques ou préparations similaires pour la toilette caractérisés par une forme physique particulière
A61L 31/06 - Matériaux macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 31/12 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
29.
ARTIFICIAL NEURAL NETWORK ON QUANTUM COMPUTING HARDWARE
The invention concerns artificial neural networks on quantum computing hardware via a circuit capable of performing neuromorphic operations in a quantum computing environment. It is based on a recent demonstration of a quantum computing version of a single artificial neuron, that performs exponentially better than the classical counterpart when considering the amount of information it can store and elaborate. The present invention combines such neurons via the use of quantum synapses into an artificial (e.g. deep) neural network that will show the same plasticity and ability to undergo machine learning as classical neural networks, while still retaining the exponential advantage coming from the quantum neurons.
The invention concerns an electro-optical modulator, wherein a band-edge slow light in silicon waveguide gratings is applied to Mach- Zehnder modulators based on the plasma dispersion effect. An interleaved p-n junction with the same periodicity as the grating is used, in order to achieve optimal matching between the electromagnetic field profile and the depletion regions of the p-n junction. The resulting modulation efficiency is strongly improved as compared to common modulators based on normal rib waveguides, even in a bandwidth of 20-30 nm near the band edge, while the total insertion loss due to free carriers is not increased. The present invention allows production of slow-light modulators for silicon photonics with reduced energy dissipation.
G02F 1/025 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des éléments à semi-conducteurs ayant au moins une barrière de potentiel, p.ex. jonction PN, PIN dans une structure de guide d'ondes optique
G02F 1/225 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur par interférence dans une structure de guide d'ondes optique
31.
SYSTEM FOR THE DETERMINATION OF THE SURFACE AND MECHANICAL CHARACTERISTICS OF FILAMENTARY STRUCTURES, IN PARTICULAR SKIN APPENDAGES, STRUCTURES ASSOCIATED THEREWITH, NATURAL OR SYNTHETIC FIBERS AND THEIR AGGREGATES
A system is described for the characterization of vital or reconstituted tissues, in particular skin appendages such as hair or eyelashes or structures associated therewith, comprising in combination: a plurality of sources (12) of electromagnetic radiations adapted to be oriented spatially and to irradiate according to a selected angle of incidence a sample (S) of vital or reconstituted tissue comprising a series of filaments of a person which are homogenous in their structural type; at least one image acquisition device (14) adapted to receive a reflected and/or dispersed radiation from the sample (S), or a fluorescence radiation emitted by the sample (S); and an image processing unit (18) designed to process reflection and/or dispersion images and/or fluorescence images, and to classify the tissue being examined in order to compare the value of at least one out of the parameters of gloss, dimensions, colour intensity, contour of the filaments of the sample (S) with a database of parameters of classes of predetermined vital or reconstituted tissues, and/or to compare the value of at least one out of the parameters of gloss, dimensions, colour intensity, contour of the filaments of the sample (S) with a database of historic values of parameters of the tissue.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/103 - Dispositifs de mesure pour le contrôle de la forme, du dessin, de la dimension ou du mouvement du corps ou de parties de celui-ci, à des fins de diagnostic
A61B 5/107 - Mesure de dimensions corporelles, p.ex. la taille du corps entier ou de parties de celui-ci
The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.
C07K 16/12 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
The present invention relates to a process for preparing nanofibers and nanofiber membranes and to the nanofibers and nanofiber membranes obtainable by such process.
The present invention relates to a three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures, and to a method for preparing it, where said three-dimensional substrate comprises: - a diffusion system (1) which comprises a first compartment (2) and a second compartment (3), where said first compartment (2) is placed above said second compartment (3), said first and second compartments (2, 3) being separated by a semipermeable membrane (4); - a base solution which comprises polysaccharides, proteins and salts or a preformed hydrogel which comprises polysaccharides, proteins and salts; - a cross-linking medium which comprises salts, culture media and distilled water.
The present invention relates to a three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures, and to a method for preparing it, where said three-dimensional substrate comprises: - a diffusion system (1) which comprises a first compartment (2) and a second compartment (3), where said first compartment (2) is placed above said second compartment (3), said first and second compartments (2, 3) being separated by a semipermeable membrane (4); - a base solution which comprises polysaccharides, proteins and salts or a preformed hydrogel which comprises polysaccharides, proteins and salts; - a cross-linking medium which comprises salts, culture media and distilled water.
The present invention regards a process for producing a photosensitive resin for 3D printing comprising a step (i) of treating a vegetable oil with a polyol to form a monoglyceride, a step (ii) of reacting the monoglyceride of step (i) with an unsaturated reagent to form a liquid resin with viscosity lower than 20 Pa s at the temperature of 20°C, and a step (iii) of mixing the liquid resin with a comonomer and a photoinitiator, as well as the photosensitive resin for 3D printing obtainable from such process and the 3D object obtainable from such photosensitive resin.
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
G03F 7/027 - Composés photopolymérisables non macromoléculaires contenant des doubles liaisons carbone-carbone, p.ex. composés éthyléniques
G03F 7/029 - Composés inorganiques; Composés d'onium; Composés organiques contenant des hétéro-atomes autres que l'oxygène, l'azote ou le soufre
G03F 7/031 - Composés organiques non couverts par le groupe
G03F 7/038 - Composés macromoléculaires rendus insolubles ou sélectivement mouillables
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Electronic system for detecting the margin between tumour mass in a tissue and healthy tissue, comprising an electronic processing unit (U) which controls a detection probe (2) with an elongated shape and which is traversable. This probe comprises at least one electromagnetic sensor in the microwave frequency range capable of obtaining the dielectric permittivity of the tissue.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio
41.
MUTANT ALCOHOL OXIDASES AND USE THEREOF IN THE CONVERSION OF DIOLS AND POLYOLS
Gloeophyllum trabeumCandida, boidinii Pichia pastorisPichia angustaPichia angusta (PaAOX; SEQ ID NO:5), and comprising one or more of the following mutations: (i) the amino acid corresponding to Phe at position 101 of PcAOX is mutated to Gin, Asn, His or Ser; (ii) the amino acid corresponding to Met at position 103 of PcAOX is mutated to Ser, Ala, Gly, Pro or Cys; (iii) the amino acid corresponding to Leu at position 317 of PcAOX is mutated to Val, He, Ala or Met; (iv) the amino acid corresponding to Tyr at position 407 of PcAOX is mutated to Phe, Val, Leu, He or Met; (v) the amino acid corresponding to Trp at position 560 of PcAOX is mutated to Cys, Met, Ala, Val, Leu or Ile.
The present invention generally relates to a MPNs marker and particularly to a biomarker associated with MF. The present invention provides a method for diagnosis, prognosing or staging MPNs, in particular PMF, by measuring a specific marker. Accordingly, a first aspect of the present invention relates to an assay method for the detection and quantification of the levels of EDA FN in a biological sample. Moreover, a second aspect of the present invention relates to a method for diagnosis, prognosing or staging MF in a living subject based on the measured levels of EDA FN.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
The present invention relates to a process for preparing nanofibers and nanofiber membranes and to the nanofibers and nanofiber membranes obtainable by such process.
It is disclosed a method for manufacturing a ceramic object, the method comprising the following steps: providing a sample of the object by means of a three-dimensional printing technology, wherein the sample is made from a precursor material comprising a material comprising carbon, and an inorganic component; and submitting the sample to a thermal treatment comprising a process involving the reaction of the carbon with the inorganic component in order to obtain the ceramic object.
C04B 35/56 - Produits céramiques mis en forme, caractérisés par leur composition; Compositions céramiques; Traitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base de non oxydes à base de carbures
B22F 3/105 - Frittage seul en utilisant un courant électrique, un rayonnement laser ou un plasma
C04B 35/573 - Céramiques fines obtenues par frittage par réaction
C04B 35/65 - Frittage par réaction de compositions contenant un métal libre ou du silicium libre
B29C 64/124 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p.ex. modélisation par dépôt de fil en fusion [FDM]
C04B 35/653 - Procédés comportant une étape de fusion
B28B 1/00 - Fabrication d'objets façonnés à partir du matériau
45.
A HIGHLY STABLE, PROTEASE-RESISTANT E. COLI ASPARAGINASE
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Espagne)
UNIVERSITÀ DEGLI STUDI DI PAVIA (Italie)
UNIVERSITAT JAUME I (Espagne)
Inventeur(s)
Morales Sánchez, Juan Carlos
Pérez-Victoria Moreno De Barreda, José María
Arévalo Ruíz, Matilde
Belmonte Reche, Efres
Martínez García, Marta
Lucas Rodríguez, Ricardo
López Rubio, José Juan
Freccero, Mauro
Doria, Filippo
Carda Usó, Pedro Miguel
Falomir Ventura, Eva
Abrégé
The invention relates to novel compounds which are naphthalene diimide sugar conjugates of general formula (I) and its procedure of obtainment. The compounds of the invention are used in therapy; particularly they have shown antiproliferative, antitrypanosomal and antimalarial activity.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
It is described a surgical instrument to facilitate the introduction of the internal component of a cochlear implant, CI, comprising two crossed arms connected by a joint, wherein each arm acts as a first class lever and the joint acts as a fulcrum, wherein the tool comprises two rings, one for each arm, configured to accommodate two fingers of the hand of a surgeon, characterized by comprising a retainer for retaining a portion of said inner cochlear implant component, wherein said retainer comprises two movable half-cylinders which are hinged one to each other.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux, p.ex. tourniquets
The present invention relates to a mutation of the catalytic domain of a NADPH oxidase (NOX) and the use thereof to facilitate crystal structure determination, and to the corresponding mutated form of NOX and the use thereof to design and produce chemical scaffolds for the generation of NOX ligands effective in different diseases.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT PASTEUR DE LILLE (France)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italie)
UNIVERSITÉ DE LILLE (France)
Inventeur(s)
Vicogne, Jerome
Melnyk, Oleg
Ollivier, Nathalie
Adriaenssens, Eric
Leclercq, Berenice
Simonneau, Claire
De Nola, Giovanni
Gherardi, Ermanno
De Jonge, Hugo
Abrégé
Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.
C07K 14/475 - Facteurs de croissance; Régulateurs de croissance
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
A61K 38/18 - Facteurs de croissance; Régulateurs de croissance
A61K 38/00 - Préparations médicinales contenant des peptides
50.
OPTICAL TRANSMITTER FOR FIBER OPTIC COMMUNICATIONS
It is disclosed an optical transmitter for a network apparatus of a fiber optic communication network. The optical transmitter comprises an optical source in turn comprising an optical cavity and a phase modulator inside the optical cavity. The optical transmitter further comprises an electrical signal generator configured to encode, according to a return-to-zero scheme, a sequence of bits to be transmitted as a multi-level electrical signal for driving the phase modulator to generate a multi-level phase modulated optical signal.
H04B 10/50 - Systèmes de transmission utilisant des ondes électromagnétiques autres que les ondes hertziennes, p.ex. les infrarouges, la lumière visible ou ultraviolette, ou utilisant des radiations corpusculaires, p.ex. les communications quantiques Émetteurs
H01S 5/06 - Dispositions pour commander les paramètres de sortie du laser, p.ex. en agissant sur le milieu actif
H04B 10/516 - Systèmes de transmission utilisant des ondes électromagnétiques autres que les ondes hertziennes, p.ex. les infrarouges, la lumière visible ou ultraviolette, ou utilisant des radiations corpusculaires, p.ex. les communications quantiques Émetteurs - Détails du codage ou de la modulation
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT PASTEUR DE LILLE (France)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italie)
UNIVERSITE DE LILLE (France)
Inventeur(s)
Vicogne, Jerome
Melnyk, Oleg
Ollivier, Nathalie
Adriaenssens, Eric
Leclercq, Berenice
Simonneau, Claire
De Nola, Giovanni
Gherardi, Ermanno
De Jonge, Hugo
Abrégé
The present invention relates to proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration.
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
52.
MULTIMERIC COMPOUNDS OF A KRINGLE DOMAIN FROM THE HEPATOCYTE GROWTH FACTOR / SCATTER FACTOR (HGF/SF)
UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE-LILLE 1 (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT PASTEUR DE LILLE (France)
UNIVERSITE DE LILLE 2 DROIT ET SANTE (France)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italie)
Inventeur(s)
Vicogne, Jerome
Melnyk, Oleg
Ollivier, Nathalie
Adriaenssens, Eric
Leclercq, Berenice
Simonneau, Claire
De Nola, Giovanni
Gherardi, Ermanno
De Jonge, Hugo
Abrégé
The present invention relates to multimeric compounds of K1 domains from the Hepatocyte Growth Factor / Scatter Factor (HGF/SF) being able to induce activation of the tyrosine kinase receptor MET and their uses.
C07K 14/475 - Facteurs de croissance; Régulateurs de croissance
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE-LILLE 1 (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT PASTEUR DE LILLE (France)
UNIVERSITE DE LILLE 2 DROIT ET SANTE (France)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italie)
Inventeur(s)
Vicogne, Jerome
Melnyk, Oleg
Ollivier, Nathalie
Adriaenssens, Eric
Leclercq, Berenice
Simonneau, Claire
De Nola, Giovanni
Gherardi, Ermanno
De Jonge, Hugo
Abrégé
The present invention relates to proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration.
C07K 14/475 - Facteurs de croissance; Régulateurs de croissance
A61K 38/00 - Préparations médicinales contenant des peptides
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
The present invention relates to an oil-in-water nanoemulsion comprising an oil phase comprising at least one essential oil or water- immiscible phase comprising a hydrophobic polymer and/or a hydrophobic active dispersed in an aqueous phase, said nanoemulsion comprising nanometric droplets of said essential oil or said active with an interface consisting of amphiphilic derivatives of chitosan and at least one fatty acid, obtained by ionic interaction between the deacetylated amino groups of said chitosan and the carboxylic groups of said fatty acid.
The present invention relates to the use of arylalkanolamine compounds with sigma-1 receptor antagonist activity. In particular, the said arylalkanolamine compounds are useful in the treatment of conditions selected from the abuse of psychotropic substances such as cocaine or amphetamines, pain and cancer.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/4453 - Pipéridines non condensées, p.ex. pipérocaïne substituées uniquement en position 1, p.ex. propipocaïne, dipérodone
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
A61K 31/54 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. sulthiame
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
56.
SYSTEM FOR DETERMINING THE MORPHOLOGICAL CHARACTERISTICS AND MECHANICAL PROPERTIES OF LIVING OR RECONSTITUTED TISSUES, IN PARTICULAR CUTANEOUS APPENDAGES, OR STRUCTURES ASSOCIATED THEREWITH
A system is described for characterizing living or reconstituted tissues, in particular cutaneous appendages such as nails and the like or structures associated therewith, comprising: - a plurality of supports (12a- 12c) for a cutaneous appendage (N) under test, each of which is adapted to form at least one point of support of the cutaneous appendage (N) when this is subjected to application of a predetermined characterizing force; an image acquisition device (20) of the cutaneous appendage (N) under test, adapted to acquire a plurality of successive images over time representative of the geometric configuration of the cutaneous appendage (N); and a processing unit (30) coupled to the image acquisition device (20) and adapted to correlate the acquired images representative of the geometric configuration of the cutaneous appendage (N) with the characterizing forces applied.
SCUOLA UNIVERSITARIA PROFESSIONALE DELLA SVIZZERA ITALIANA (Suisse)
NEMBRI INDUSTRIE TESSILI S.R.L. (Italie)
INNOVHUB - STAZIONI SPERIMENTALI PER L'INDUSTRIA (Italie)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italie)
CENTRO TESSILE SERICO - SOCIETA' CONSORTILE PER AZIONI (Italie)
Inventeur(s)
Iamartino, Piero
Longhi, Renzo
Sorlini, Marzio
Nembri, Giorgio
Farago', Silvio
Torre, Maria Luisa
Gatti, Francesco
Abrégé
The present invention relates to spray compositions comprising fibroin and a co-micronised alginic acid salt, a micronised calcium salt and a source of silver and/or copper, and the corresponding manufacturing processes.
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61K 31/191 - Acides acycliques ayant plusieurs groupes hydroxyle, p.ex. acide gluconique
It is disclosed a two-photon excited fluorescence microscope comprising a laser source suitable for emitting a light beam and an optical arrangement suitable for receiving the light beam from the laser source. The optical arrangement is configured for shaping the light beam so that, at the output of the microscope, the light beam is substantially collimated in a first transverse direction perpendicular to the propagation direction of the light beam at the microscope output and is focused in a second transverse direction perpendicular to the first transverse direction and to the propagation direction, thereby forming a line parallel to the first transverse direction.
Universita Degli Studi di Roma “La Sapienza” (Italie)
Fondazione IEO (Italie)
Universita Degli Studi di Pavia (Italie)
Universita Degli Studi di Milano (Italie)
Inventeur(s)
Minucci, Saverio
Mai, Antonello
Mattevi, Andrea
Abrégé
3 are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to compositions containing them and to therapeutic use thereof.
UNIVERSITA DEGLI STUDI DI ROMA "LA SAPIENZA" (Italie)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italie)
UNIVERSITA' DEGLI STUDI MILANO (Italie)
FONDAZIONE ISTITUTO EUROPEO DI ONCOLOGIA E CENTRO CARDIOLOGICO FONDAZIONE MONZINO (Italie)
Inventeur(s)
Minucci, Saverio
Mai, Antonello
Mattevi, Andrea
Abrégé
Tranylcypromme derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized by deregulation of gene transcription, cell differentiation and proliferation, e g tumors, viral infections, are herem described. These compounds belong to the structural formula (I) wherein A and R3 are as defined in the specification The invention also relates to the preparation of these compounds, as well as to compositions containing them and to therapeutic use thereof.
C07C 233/43 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes amino avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné saturé
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/17 - Amides, p.ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p.ex. urée, thiourée, carmustine
A61K 31/325 - Acides carbamiques; Acides thiocarbamiques; Leurs anhydrides ou sels
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
C07C 233/44 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes amino avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons ayant l'atome de carbone du groupe carboxamide lié à un atome de carbone d'un squelette carboné non saturé
C07C 233/80 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes amino avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons
C07C 271/22 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec les atomes d'azote des groupes carbamate liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone de radicaux hydrocarbonés substitués par des groupes carboxyle
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
C07C 275/24 - Dérivés d'urée, c. à d. composés contenant l'un des groupes les atomes d'azote ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes urée liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant des cycles aromatiques à six chaînons
C07D 333/60 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile
61.
TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE LSD1 AND/OR LSD2
UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (Italie)
FONDAZIONE IEO (Italie)
UNIVERSITÀ DEGLI STUDI DI PAVIA (Italie)
UNIVERSITÀ DEGLI STUDI DI MILANO (Italie)
Inventeur(s)
Minucci, Saverio
Mai, Antonello
Mattevi, Andrea
Abrégé
Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized by deregulation of gene transcription, cell differentiation and proliferation, e.g. tumors, viral infections, are herein described. These compounds belong to the structural formula (I) wherein A and R3 are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to compositions containing them and to therapeutic use thereof.
C07C 233/43 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes amino avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné saturé
C07C 233/44 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes amino avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons ayant l'atome de carbone du groupe carboxamide lié à un atome de carbone d'un squelette carboné non saturé
C07C 233/80 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes amino avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons
C07C 271/22 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec les atomes d'azote des groupes carbamate liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone de radicaux hydrocarbonés substitués par des groupes carboxyle
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
C07C 275/24 - Dérivés d'urée, c. à d. composés contenant l'un des groupes les atomes d'azote ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes urée liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant des cycles aromatiques à six chaînons
C07D 333/60 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/17 - Amides, p.ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p.ex. urée, thiourée, carmustine
A61K 31/325 - Acides carbamiques; Acides thiocarbamiques; Leurs anhydrides ou sels
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
The present invention concerns a system as well as a method for the evaluation of the vestibular functionality in a subject. The system comprises a display unit for showing a visual target such as an optotype to the patient, a device for measuring rotational acceleration that rotates integrally with the patient's head, and a recording unit. The method of the invention may also be suitably used for the rehabilitation of the peripheral vestibular functionality.
A61B 3/028 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure subjective, c. à d. appareils de d’examen nécessitant la participation active du patient pour la détermination de la réfraction, p.ex. phoromètres
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
63.
PLATELETS LYSATE AND BIOADESIVE COMPOSITIONS THEREOF FOR THE TREATMENT OF MUCOSITIS
The present invention concerns the use of platelet lysate for treating and/or preventing mucositis. Moreover, a mucoadhesive composition comprising such a platelet lysate for the therapy and/or prevention of mucositis and of corneal lesions is described.
The present invention relates to a screening method for the identification of new benzothiazinone drugs for the treatment of tuberculosis. The method comprises the use of the nitroreductase Nfnb from Mycobacterium smegmatis GM22, which has no mutation compared to other mycobateria nitroreductases.
C12Q 1/26 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une oxydoréductase
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
The present invention discloses a new L-asparaginase from Helicobacter pylori. The recombinant enzyme cloned from Escherichia coli has been isolated, purified and characterized. It can be used as a new therapeutic and diagnostic tool. Further, its application as a food additive has been disclosed.
is disclosed a device for manipulating a particle immersed in a fluid, comprising a probe having a first end, a second end and a longitudinal axis. The probe receives a radiation from a light source and emits the radiation by means of the second end. The probe comprises: an optical guide structure suitable for receiving the radiation. The optical guide structure is configured so that: at the second end, the radiation has an optical intensity distribution with an intensity maximum placed at a non- zero distance from the longitudinal axis of the probe;and in the region of the intensity maximum, the radiation is reflected at the interface between the second end and the fluid and is emitted by the second end so that it converges in a convergence point, thus creating an equilibrium point. The probe further comprises perturbation optical means for perturbing the equilibrium point.
It is disclosed an optical device for trapping a particle immersed in a fluid. The device of the invention comprises a light source and a probe for guiding and outputting the radiation received from the source. According to the invention, the guided radiation has an intensity distribution having intensity maximum placed at a non-zero distance from the probe longitudinal axis and having rotational symmetry about the longitudinal axis. Further, according to the invention, the intensity maximum is reflected at the interface between probe and fluid, and then it is output by the probe so that it creates a stable equilibrium point wherein the particle is trapped.
Object of the invention is an interactive dressing the treatment of dermatological disorders. The invention comprises: a support, preferably a tissue non-tissue gauze, a hydrogel of a bioadhesive polymer like chitosan or hydroxyethylcellulose and liposomal systems containing an active principle of protein nature. It is a solid therapeutic system consisting of a dispersion of liposomes in hydrogel adsorbed on a tissue non-tissue gauze. The association of hydrogel with liposomal systems allows the site specific and prolonged release of active substances, through intracellular transfer of liposomes and therefore of the encapsulated drug. In addition to act as a storage form, liposomes protect the drug from enzymatic attacks, thus preserving its activity. The therapeutic system containing preferably the prolidase enzyme is used for the treatment, in human and mammals, of dermatological disorders with or without epithelial ulcers, preferably for treatment of ulcers in subjects affected by genetic prolidase deficiency.
A61L 15/38 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p.ex. serviettes hygiéniques, tampons contenant des enzymes
A61L 15/32 - Protéines, polypeptides; Leurs produits de dégradation ou leurs dérivés, p.ex. albumine, collagène, fibrine, gélatine
A61L 15/20 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p.ex. serviettes hygiéniques, tampons contenant des matériaux organiques
69.
MICROPARTICULATE SYSTEMS FOR THE ORAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES
The present invention relates to gastroresistant and enterosoluble microparticulate systems for the encapsulation of biologically active substances selected from: flavonoids, vitamins, antioxidants, immunostimulants, starchy and non-starchy polysaccharides, probiotics, prebiotics, intestinal trophism regulators, oligoelements, enzymes and bioactive peptides. Such microparticulate systems allow the administration of the aforementioned nutraceutic substances to animals such as porcines, bovines, caprines, ovines, equids, canids, felines, camelids, lagomorphs, rodents, fowl, and other mammals, including humans, fish and crustaceans, increasing the bioavailability.
The present invention relates, in general, to devices for optimising image-taking, to optical components comprised in said devices and to a method for optimising image- taking in applications wherein photo-detecting elements with pixel-board processing are provided. The device comprises an objective (110) arranged for focalising the image or optical information on a focal plane (12) and at least one chip (120) of photo-detecting elements with pixel-board processing (112) having photo-sensitive elements (46) and circuit elements (48). The device further comprises at least one optical component (100) having a plurality of concentrators (41) and corresponding optical elements shaped so as to collect the optical information present in the focal plane (12) and concentrate said optical information on the photo-sensitive elements (46).
H01L 27/148 - Capteurs d'images à couplage de charge
H04N 5/335 - Transformation d'informations lumineuses ou analogues en informations électriques utilisant des capteurs d'images à l'état solide [capteurs SSIS]
71.
MUTATIONS ASSOCIATED WITH THE LONG QT SYNDROME AND DIAGNOSTIC USE THEREOF
FONDAZIONE SALVATORE MAUGERI CLINICA DEL LAVORO E DELLA RIABILITAZIONE I.R.C.C.S. (Italie)
UNIVERSITA' DEGLI STUDI DI PAVIA (Italie)
Inventeur(s)
Priori, Silvia Giuliana
Abrégé
The present invention is based on the identification of new mutations in KCNQ1 (also termed KvLQTI), KCNH2 (also termed HERG), SCN5A, KCNE1 (also termed minK), KCNE2 (also termed MiRP) genes that encode ionic channels involved in cardiac electrical activity and are potentially responsible for the Long QT Syndrome. According to a main aspect, the invention relates to nucleic acids, oligonucleotides and polynucleotides and mRNA, containing sequences of KCNQ1 , KCNH2 SCN5A, KCNE1 , KCNE2 genes and cDNAs in a mutated form and to respective variant proteins thereof. A preferred embodiment of the present invention is represented by a diagnostic method based on the identification of a group of about 70 non-private mutations in the KCNQ1 , KCNH2 and SCN5A genes, detected at high frequency. The method, which is able to identify about 40% of the probands, is non exclusively based on identification of mutations that are described and characterized in this invention where said identification has both prognostic and diagnostic value for the Long QT Syndrome.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
72.
CAPSULES CONTAINING SEMINAL MATERIAL FOR ARTIFICIAL INSEMINATION
Capsules or microcapsules comprising: a) a nucleus containing seminal material or the spermatozoa of animal species chosen from the group consisting of equids, buffalo, ovicaprids, canids, felids, lagomorphs, laboratory animal species chosen from mice and rats, and possibly man, b) a membrane of a bivalent or trivalent metal alginate.